A company says it is developing a small molecule drug without major safety issues to treat a growing number of cases of atrial fibrillation, the most common cardiac arrhythmia.
Positive data from a phase 2 clinical trial has proven the general mechanism of action of SK channel inhibition for treatment of atrial fibrillation (AF), an abnormal heart rhythm.
The company is joining with the Thrombosis Research Institute on the creation of a heart disease patient dataset to advance precision medicine development.
The US-based company continues its move away from smoking products with the purchase of drug developer OtiTopic, as part of its Beyond Nicotine initiative.
The BiovitalsHF, from Biofourmis, is intended to augment decision-making in clinical environments, and to supplement traditional pharmaceutical therapies.
A recent survey conducted by dosing technology firm found that the vast majority (85%) of patients think that personalized medicine stands to improve care.
A recent study indicates patients taking the cholesterol-lowering drugs prior to COVID hospitalization are far less likely to die as a result of the virus.
The American Heart Association’s Heart of Communicating Science modules are designed to help experts break complex talk into easy-to-understand language.
The trials, funded by the American Heart Association, will harness the company’s Verisense wearable sensor platform to examine brain-heart health links.
The pharma firm and health association plan to collaborate in order to help drive global action toward prevention and control of cardiovascular disease.
Researchers develop organ-on-an-electronic-chip platform to explore the electrophysiology of iPSC-derived cardiomyocytes and understand how the heart communicates.
A study by Biofourmis aims to improve patient centricity in the drug approval processes by using wearable technology and mobile software to monitor the quality of life for patients with heart failure.
Researchers at London, UK-based Imperial College are developing a technology to transport drugs directly to the lungs of pulmonary arterial hypertension (PAH) patients.
While there are currently several techniques for producing tissue from heart cells, a new method reduces the amount of cells needed, making it easier and cheaper to replicate.
CRO Theorem Clinical Research and service provider Biomedical Systems have formed a strategic partnership to expand the type of services available to their clients worldwide.
Sinobiopharma is seeking a Chinese patent covering the manufacture of capsule forms of the heart drug perindopril, claiming it is the first company in the world to produce the medication in this easy to swallow format.
Schering-Plough has licensed acadesine (AICA-riboside), a potential
first-in-class drug for the prevention of ischemia-reperfusion
injury from PeriCor Therapeutics to bolster its cardiac
therapeutics pipeline.
While the market performance of Exubera may have fallen short of
expectations, Pfizer's inhaled insulin has opened the door for a
wider variety of macromolecules to take the pulmonary delivery
route.
The US Food and Drug Administration (FDA) has decided against
restricting the use of drug-eluting cardiac stents after a two-day
investigation into their potential to increase blood clots.
The recent discovery of master cardiac stem cells with the capacity
to produce all three major heart tissue types brings heart tissue
regeneration after injury a step closer.
Actelion has announced it is acquiring biopharmaceutical company
CoTherix for $420m (€328m) with the objective of taking over and
increasing the distribution of Ventavis, the only approved inhaled
therapy for the treatment of Pulmonary...
Australia's AtCor Medical will supply an undisclosed US
pharmaceutical company with central blood pressure reading and
clinical trial support services in a deal worth $1.48m (€1.2m).
Scientists at the Georgia Institute of Technology have developed a
small handheld device that makes finding veins easier and quicker,
saving time and money.
The latest research included in the proceedings of the annual
meeting of the European Society of Cardiology, (ESC) means that
heart treatments and management therapies feature strongly in
DrugResearcher's round-up of the 5-day...
Scientists have admitted that women who take heart drugs are taking
unknown risks after a review of existing data has shown that these
drugs can affect women differently.
Cardiome Pharma has completed its second Phase I trial for the
controlled release oral formulation of RSD1235, an anti-arrhythmic
drug candidate that could well provide an effective drug therapy
for its 7 million sufferers worldwide.
US researchers have found a delivery method for gene therapy that
reaches all the voluntary muscles of a mouse - including heart,
diaphragm and limbs - and reverses the process of muscle-wasting
found in muscular dystrophy.
3M has teamed up with MicroDose Technologies to market a new
metered dose inhaler that should be cheap to produce and deliver a
broad range of compounds.
Occam International of the Netherlands has licensed its coating
technology to Xtent, a company specialising in the development of
cardiovascular stents that deliver drugs directly into the blood
vessels.
A new type of drug to treat the cardiovascular disease stable
angina, a chronic condition marked by recurrent episodes of
suffocating chest pain from lack of oxygen to the heart muscle, has
shown encouraging safety and efficacy in...
